Cathie Wood's Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic ...

The FDA granted priority review to Intellia Therapeutics' gene-editing therapy lonvoguran Ziclumeran for a rare genetic disorder, hereditary angioedema, with a decision due by March 10, 2027. Intellia's trial showed significant reduction in attacks and no serious adverse events, marking a potential first for in vivo CRISPR therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.